title: Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.
abstract: OBJECTIVE
  99mTc-3PRGD2, a promising tracer targeting integrin receptor, may serve as a novel tumor-specific agent for single photon emission computed tomography (SPECT). A multi-center study was prospectively designed to evaluate the diagnostic accuracy of 99mTc-3PRGD2 imaging for bone metastasis in patients with lung cancer in comparison with the conventional 99mTc-MDP bone scan.
  
  
  METHODS
  The patients underwent whole-body scan and chest tomography successively at both 1 h and 4 h after intravenous injection of 11.1 MBq/Kg 99mTc-3PRGD2. 99mTc-MDP whole-body bone scan was routinely performed within 1 week for comparison. Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images. The final diagnosis was established based on the comprehensive assessment of all available data.
  
  
  RESULTS
  A total of 44 patients (29 male, 59±10 years old) with suspected lung cancer were recruited from 4 centers. Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign. In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively. The corresponding diagnostic values for 99mTc-MDP bone scan were 87.6%, 60.9%, and 82.1%, respectively in the same patients. 99mTc-MDP bone scan had better contrast in most lesions, whereas the 99mTc-3PRGD2 imaging seemed to be more effective to exclude pseudo-positive lesions and detect bone metastases without osteogenesis.
  
  
  CONCLUSIONS
  99mTc-3PRGD2 is a novel tumor-specific agent based on SPECT technology with a promising value in diagnosis of bone metastasis in patients with lung cancer.
  
  
  BACKGROUND
  ClinicalTrials.gov NCT01737112.
authors.affiliation: Department of Nuclear Medicine, the 1st Affiliated Hospital of Fujian Medical University, Fuzhou, China.
authors.forename: Weibing
authors.initials: W
authors.lastname: Miao
authors.affiliation: Department of Nuclear Medicine, the 1st Affiliated Hospital of Fujian Medical University, Fuzhou, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Zheng
authors.affiliation: Department of Nuclear Medicine, Beijing Tongren Hospital, Beijing, China.
authors.forename: Haojie
authors.initials: H
authors.lastname: Dai
authors.affiliation: Department of Nuclear Medicine, the 1st Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.affiliation: Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
authors.forename: Xiaona
authors.initials: X
authors.lastname: Jin
authors.affiliation: Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Zhu
authors.affiliation: Medical Isotopes Research Center, Peking University, Beijing, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Jia
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds; D010456:Peptides, Cyclic; D013669:Technetium Tc 99m Medronate; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D015609:Organotechnetium Compounds; D010456:Peptides, Cyclic; C561921:technetium 99m (HYNIC-3PRGD(2))(tricine)(TPPTS); D013669:Technetium Tc 99m Medronate